Peritoneal Mesothelioma

What Is Peritoneal Mesothelioma?

Mesothelioma of the peritoneum is a rare asbestos-related cancer that forms on the abdominal lining. A rare form of this cancer develops in the omentum, a layer of the abdominal membrane that covers the stomach and other organs.

The beginning symptoms of peritoneal mesothelioma include abdominal distension, abdominal pain, swelling or tenderness around the abdomen and constipation or diarrhea.

Important Facts About Peritoneal Mesothelioma

• It accounts for less than 20% of all mesothelioma cases.
• Surgery with heated chemotherapy is the most effective treatment.
• Immunotherapy for this type is available through clinical trials.
• Surgical peritoneal patients live four times longer than the average pleural mesothelioma patient

What Causes Peritoneal Mesothelioma?

Ingesting asbestos fibers causes malignant peritoneal mesothelioma. Researchers do not fully understand how, but they have developed theories about how asbestos fibers reach the abdomen and result in cancer.

Research on other causes of abdominal mesothelioma is scarce. Evidence shows other fibrous minerals, such as erionite, and radiation to the abdomen trigger some cases of this disease.

Learn More About How Asbestos Causes Mesothelioma

What Are the Symptoms of Peritoneal Mesothelioma Cancer?

• Abdominal pain or swelling
• Diarrhea or constipation
• Changes in bowel habits
• A feeling of fullness
• Night sweats or fever
• Unexplained weight loss
• Nausea or vomiting
• Fatigue
• Anemia

How Is Peritoneal Mesothelioma Diagnosed?

Abdominal mesothelioma is diagnosed with imaging scans, blood tests and biopsies.

• Imaging scans show the size and location of tumors.
• Blood tests reveal certain biomarkers associated with cancer.
• Biopsies show what kind of cancerous cells are present.

Patients will also receive a thorough examination of their medical history, occupational history and overall physical condition.

While every test serves a contributing purpose to the diagnostic process, the only way to confirm a peritoneal mesothelioma diagnosis is with a biopsy.

Biopsies are samples of tumor tissue that are examined under a microscope in a lab. Medical professionals called pathologists perform tests on the biopsy sample to reveal what kinds of cancerous cells are within the tumors, which is summarized in a pathology report.

Learn More About How to Test for Mesothelioma

Diagnosing Cell Types of Peritoneal Mesothelioma

The pathology report will contain information about the cellular subtype of your peritoneal mesothelioma.

Common Cell Types

• Epithelioid cells are the most common, making up 75% of cases.
• The biphasic type, which is a combination of epithelioid and sarcomatoid cells, the second most common. It makes up about 25% of cases.

Epithelioid peritoneal mesotheliomas can grow in four different patterns: Papillary (the most common, which is usually found alongside other patterns), tubular, diffuse and deciduoid.

Pure sarcomatoid tumors are extremely rare in peritoneal mesothelioma. Around 30 cases have been diagnosed since 2006. They usually occur alongside epithelioid cells to form the biphasic subtype.

Rare Cell Types

• Well-differentiated papillary mesothelioma
• Multicystic mesothelioma
• Desmoplastic mesothelioma
• Lymphohistiocytoid mesothelioma
• Pure sarcomatoid mesothelioma

Additionally, omental mesothelioma is a rare type of mesothelioma that forms in the omentum, a part of the peritoneum that connects the stomach with other abdominal organs.

Misdiagnosis

Because this cancer is rare, doctors lacking experience with the disease often misdiagnose abdominal mesothelioma patients with more common illnesses that share similar symptoms. This can delay proper treatment.

If you have a history of asbestos exposure, the best way to ensure an accurate diagnosis is to schedule an appointment with a specialist. Doctors who specialize in peritoneal mesothelioma have the knowledge and tools needed to make an accurate diagnosis.

Learn More About Mesothelioma Misdiagnosis

Peritoneal Mesothelioma Staging

For decades, peritoneal mesothelioma experts developed their own staging system because an official one didn’t exist.

In 2011, researchers proposed three stages based on surgical cases. This staging system hasn’t been officially adopted because more data is required to confirm it, but many specialists use this system already.

3 Stages of Peritoneal Mesothelioma

• Stage 1: Cancerous tissue is minimal, tumors are contained within the abdominal lining, and lymph nodes are free of cancer.
• Stage 2: Cancerous tissue is moderate, and tumors have not spread outside the lining or to lymph nodes.
• Stage 3: Cancerous tissue is more extensive, and tumors may have spread outside the peritoneal lining, to lymph nodes or both.

A fourth stage is not yet clearly defined. It is generally accepted that patients with extensive tumor spreading are classified as stage IV.

Learn more about the Stages of Mesothelioma

Peritoneal Cancer Index

The Peritoneal Cancer Index is a diagnostic tool doctors use to assess the location and spread of tumors on the peritoneum. It helps them determine the cancer’s stage.

The index divides the abdomen into 13 regions. Doctors assign a number (1-3) to each region based upon the largest tumor in that area. The Peritoneal Cancer Index score is found by adding up the individual scores from the 13 regions for a maximum score of 39 (13×3).

Lower index scores mean the patient may qualify for surgery. Higher index scores mean the cancer has spread too far to be surgically removed. Traditionally, a score higher than 20 indicates the patient won’t respond well to surgery.

Peritoneal Mesothelioma Treatment Options

Peritoneal mesothelioma is treated with chemotherapy or a combination of surgery with heated chemotherapy, also known as HIPEC (hyperthermic intraperitoneal chemotherapy).

More than 60% patients are diagnosed too late to qualify for surgery with heated chemotherapy, which is the most effective treatment option. Chemotherapy alone is the most commonly received treatment for this type of mesothelioma.

• Cytoreductive Surgery with Heated Chemotherapy: Cytoreductive surgery attempts to remove as much cancer as possible, then heated chemotherapy is applied locally to the abdomen before the surgery ends. Doctors only perform this procedure on a case-by-case basis. Around half of patients who undergo the procedure live five years or longer.
• Chemotherapy: Patients who don’t qualify for surgery with heated chemotherapy can receive systemic chemotherapy alone. Chemotherapy drugs can shrink peritoneal mesothelioma tumors and slow the growth and spread of cancer. Chemotherapy drugs considered effective against peritoneal mesothelioma include pemetrexed, cisplatin, carboplatin and gemcitabine.

Top Peritoneal Doctors

Paul H. Sugarbaker

Washington Cancer Center

Dr. Paul Sugarbaker is the country’s leading expert on peritoneal mesothelioma. He developed the widely renowned cytoreductive surgery and heated chemotherapy technique that changed the landscape of peritoneal cancer treatment. Many people with peritoneal mesothelioma are alive today because of Sugarbaker’s innovations.

Get in touch

J.F. Pingpank Jr.

UPMC Hillman Cancer Center

Dr. J.F. Pingpank Jr. is a peritoneal mesothelioma expert who advocates for regional therapy. The approach applies treatment locally around the cancer to limit damage to the rest of the body. Pingpank specializes in cytoreductive surgery and heated chemotherapy.

Get in touch

Suzanne Schiffman

Allegheny General Hospital

Dr. Suzanne Schiffman is a surgical oncologist at the Allegheny Health Network Cancer Institute with an expertise in complex abdominal malignancies. She has been specially trained in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Get in touch

W. Charles Conway

Ridley-Tree Cancer Center

Dr. W. Charles Conway is an expert in peritoneal mesothelioma and the Director of Surgical Oncology at Ridley-Tree Cancer Center in Santa Barbara, California. He specializes in minimally invasive robotic surgery and heated chemotherapy for peritoneal mesothelioma.

Get in touch

Palliative Treatment Options

In addition to anti-cancer treatments, many peritoneal patients receive palliative care to control symptoms and improve quality of life.

A palliative care specialist prescribes medications to control pain and side effects. They may refer patients to physical or occupational therapy or recommend complementary therapies.

Learn More About Mesothelioma Treatment

Peritoneal Mesothelioma Prognosis

The prognosis for peritoneal mesothelioma is generally poor for patients who don’t qualify for surgery. These patients tend to live about one year.

However, the prognosis for surgical candidates is significantly better. About half of those who receive surgery with heated chemotherapy live longer than five years.

The median survival of untreated peritoneal mesothelioma is six months.

Prognostic Factors

• Stage at diagnosis
• Cell type
• Tumor grade (how fast it grows)
• Gender
• Genetic mutations
• Treatments selected

Patients with tumors containing epithelial cells have a longer life expectancy than patients with sarcomatoid or biphasic cells. The tumor’s grade also impacts prognosis. Tumor grade is based upon how abnormal the cells appear, which indicates how quickly they are likely to grow and spread.

Women tend to live longer with peritoneal mesothelioma than men. When short- and long-term survival is averaged out, women live an average of 13 months, and men live six months.

Chemotherapy Survival Rates

The combination of cisplatin and pemetrexed delivered systemically has a response rate around 30% with average progression-free survival around 11.5 months and median survival around 13 months.

Chemotherapy delivered directly, not systemically, to the peritoneum without surgery has a higher response rate of 47%. Meanwhile, heated chemotherapy delivered during surgery has a response rate of 84.6%.

Research Is Improving Prognosis

In 2017, Dr. Paul Sugarbaker reported improved survival among patients who received early post-operative chemotherapy and long-term chemotherapy after cytoreductive surgery with heated chemotherapy.

All chemotherapy was intraperitoneal chemotherapy, meaning it was applied only to the peritoneum. No systemic chemotherapy was used in the study.

Of the 29 patients who had surgery with HIPEC, post-operative chemotherapy and long-term chemotherapy, 75% lived longer than five years.

Top